HT-102

DRUG3 trials

Sponsors

Suzhou HepaThera Biotech Co., Ltd.

Conditions

Chronic Hepatitis B

Phase 1

Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

CompletedNCT06744686

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2023-06-12End: 2024-06-18Updated: 2024-12-20

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruitingNCT07183306

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2024-12-30End: 2027-05-03Updated: 2025-09-19

Phase 2

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruitingNCT07245953

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2025-11-05End: 2027-05-31Target: 60Updated: 2025-11-24